Language selection

Search


Guidance on nitrosamine impurities in medications : evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products.: H164-327/2026E-1-PDF

"This guidance represents Health Canada's current thinking and recommendations on issues related to N-nitrosamine impurities (nitrosamine impurities or nitrosamines). This guidance may be subject to change as new information becomes available and if further guidance is needed for applicants and market authorization holders (MAHs)"--Background, page 1.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.966906&sl=0

Publication information
Department/Agency
  • Canada. Health Canada, issuing body.
TitleGuidance on nitrosamine impurities in medications : evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Title from cover.
  • Issued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments : évaluation et gestion des risques posés par les impuretés de N-nitrosamine dans les produits pharmaceutiques, biologiques et radiopharmaceutiques destinés à l'usage humain.
  • "Health products."
  • Includes bibliographical references (page 37).
Publishing information
  • [Ottawa] : Health Canada = Santé Canada, November 2026.
  • ©2026
Description1 online resource (iii, 64 pages) : illustrations
ISBN9781100010342
Catalogue number
  • H164-327/2026E-1-PDF
Edition
  • [November 2026 edition].
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details